Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats

Table 3 Effect of pre-treatment of rosiglitazone in cisplatin treated rats on % tumour inhibition in chemically induced breast cancer model

	0 Day	3^rd Day	6^th Day	9^th Day
Normal control	0 ± 0	0 ± 0	0 ± 0	0 ± 0
Breast cancer control	100 ± 45.22	188.26 ± 22.86	254.34 ± 19.83	282.60 ± 22.46
Rosi (8 mg/kg)	100 ± 21.24	85.84 ± 31.44	83.62 ± 38.62**^a	81.85 ± 10.27**^a
Cis (7.5 mg/kg)	100 ± 25.56	82.95 ± 23.78	72.64 ± 25.31**^a	68.60 ± 22.88***^a
PT Rosi (8 mg/kg) + Cis (7.5 mg/kg)	100 ± 40.78	79.12 ± 34.36*^a	60.67 ± 36.80**^a	54.85 ± 31.86***^a

Percentage tumor inhibition is assessed by calculating the percentage of reduction in tumor volume in the respective treated groups as compared to breast cancer control All values are expressed as mean ± SEM (n = 8). ***P < 0.001, **<0.01, *P < 0.05. a Vs Cancer Control. Where Rosi is rosiglitazone, Cis is cisplatin and PT is pretreatment.

ISSN: 1471-2407